Cypherpunk Technologies Appoints Arjun Khemani as Strategic Advisor to Enhance Privacy Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: PRnewswire
- Strategic Advisor Appointment: Cypherpunk Technologies Inc. has appointed Arjun Khemani as a Strategic Advisor, leveraging his influence in the Zcash ecosystem to provide high-level guidance that accelerates the expansion of privacy-preserving digital infrastructure.
- Corporate Treasury Growth: As of December 30, 2025, Cypherpunk holds 290,062.67 ZEC at an average price of $334.41 per ZEC, representing approximately 1.76% of the total circulating Zcash supply, underscoring the company's confidence in Zcash as a long-term asset.
- Advocacy for Privacy Technology: Khemani's appointment will strengthen Cypherpunk's position within the privacy ecosystem, as his philosophical insights are expected to foster a culture of digital self-sovereignty, thereby promoting broader adoption of privacy technologies.
- Investment Context: This appointment follows Cypherpunk's $58.88 million private placement led by Winklevoss Capital, further solidifying the company's strategic positioning in the privacy technology sector.
Analyst Views on CYPH
About CYPH
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
